

## Daftar Pustaka

- American Diabetes Association. 2004. Diabetes Mellitus And Other Categories of Description of Diabetes. *Diabetes Care*. 27:S5-10.
- Anggrahini DW. 2015. 'Hubungan antara kadar endothelin-1 sirkulasi pulmonal dengan resistensi vaskular paru pada pasien defek septum atrium sekundum dewasa', Tesis, Spesialis, Universitas Gadjah Mada, Yogyakarta.
- Bakker E.N., Matlung H.L., Bonta P., De Vries C.J., Van Rooijen N., Vanbavel E. 2008. Blood flow-dependent arterial remodeling is facilitated by inflammation but directed by vascular tone. *Cardiovascular Research*; 78: 341-348.
- Barksby H. E., Lea S. R., Preshaw P. M., Taylor J. J. 2007. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. *Clin Exp Immunol*. 149(2):217-225.
- Beghetti M, Galiè N. 2009. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. *Journal of the American College of Cardiology*; 53:733-740.
- Carlomagno G., Messalli G., Melillo R.M. 2013. Serum solubleST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. *Int J Cardiol.*; 168:1545–1547.
- Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT. 2013. ACCF/AHA Key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the american college of cardiology foundation/ american heart association task force on clinical data standards. *JACC*; 61:9.
- Chen W.Y., Li L.C., Yang J.L. 2017. Emerging Roles of IL-33/ST2 Axis in Renal Diseases *Int J Mol Sci*. Apr; 18(4): 783.
- Chida A., Sato H., Shintani M. 2014. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhood pulmonary arterial hypertension. *Circ J*. 78: 436–442.
- D'alto M, Mahadevan VS. 2012. Pulmonary arterial hypertension associated with congenital heart disease. *Eur Respir Rev*; 21:328-337.
- Daniels L.B., Clopton P., Iqbal N. 2010. Association of ST2 levels with cardiac structure and function and mortality in outpatients. *Am Heart J*. 2010;160:721–728.
- Demyanets, S., Speidl, W. S., Tentzeris, I., Jarai, R., Katsaros, K. M., Farhan, S., Krychtiuk, K. A., Wonnerth, A., Weiss, T. W., Huber, K., Wojta, J. 2014. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. *PloS one*. 9(4):e95055.
- Diller G.P., Gatzoulis M.A.. 2007. Pulmonary vascular disease in adults with congenital heart disease. *Circulation*; 115:1039-1050.
- Duffels M.G., Engelfriet P.M., Berger R.M., Van Loon R.L., Hoendermis E., Vriend J.W., Van Der Velde E.T., Besser P., Mulder B.J. 2007. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. *Int J Cardiol*; 120:198-204.
- Engelfriet P.M., Duffels M.G., Moller T., Boersma E., Tijssen J.G., Thaulow E., Gatzoulis M.A., Mulder B.J. 2007. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. *Heart*; 93:682-7.
- Farcaş A.D., Anton F.P., Goideşcu C.M., Gavrilă I.L., Vida-Simiti L.A., Stoia M.A. 2017. Serum Soluble ST2 and Diastolic Dysfunction in Hypertensive Patients Dis Markers. 2017: 2714095.

- Freixa X., Ibrahim R. 2012. Why all pulmonary hypertensive patients need a heart catheter study? *Progress in Pediatric Cardiology*; 34: 123-127.
- Geva T., Martins J.D., Wald R.M. 2014. Atrial septal defects. *The Lancet*; 383:1921-1932.
- Gottdiener J.S., Bednarz J., Devereux R., Gardin J., Klein A., Manning W.J., Morehead A., Kitzman D., Oh J., Quinones M., Schiller N.B., Stein J.H., Weissman N.J. 2004. American society of echocardiography recommendations for use of echocardiography in clinical trials. *J Am Soc Echocardiogr*; 17: 1086-1119.
- Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., Beghetti M., Corris P., Gaine S., Gibbs J.S., Gomez-Sanchez M.A., Jondeau G., Klepetko W., Opitz C., Peacock A., Rubin L., Zellweger M., Simonneau G. 2009. Guidelines for the diagnosis and treatment of pulmonary hypertension. *European Heart Journal*; 30: 2493-2537.
- Galie N., Humbert M., Vachiery K.L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Noordegraaf A.V., Beghetti M., Ghofrani A., Sanchez M.A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L.A., Trindade P.T., Zompatori M., Hoeper M. 2016. 2015 ES/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *European Heart Journal*; 37:67-119.
- Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J., Kuchler, A. M. 2009. Interleukin-33 – cytokine of dual function or novel alarmin?. *Trends in Immunology*. 30:227-233.
- Huang H., Kamm R. D., Lee, R. T. 2004. Cell mechanics and mechanotransduction: pathways, probes, and physiology. *Am J Physiol Cell Physiol*. 287:1-11.
- Humbert M., Lau E.M., Montani D., Jais X., Sitbon O., Simonneau G.. 2014. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. *Circulation*; 130:2189-2208.
- Kaemmerer H., Mebus S., Neick I.S., Eicken A., Trindade P.T., Hager A., Oechslin E., Niwa., Lang I., Hes J. 2010. The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point. *Current Cardiology Reviews*. 6: 343-355.
- Kakkar R., Lee R.T. 2008. The IL-33/ST2 pathway: therapeutic target and novel biomarker. *Nat Rev Drug Discov.*; 7:827-840.
- Kakkar R., Lee R.T. 2010. Intramyocardial Fibroblast Myocyte Communication. *Circ Res*. 106:47-57.
- Krisdinarti L., Hartopo A.B., Anggrahini D.W., Sadewa A.H., Wahab A.S., Setianto B.Y. 2016. Clinical characteristics of adult uncorrected secundum atrial septal defect: a pilot study. *J Med Sci*. 48, 2, 89-97.
- Kulik T., Mullen M., Adatia I. 2009. Pulmonary arterial hypertension associated with congenital heart disease. *Progress in Pediatric Cardiology*; 27:25-33.
- Lancellotti P., Moura L., Pierard L.A., Agricola E., Popescu B.A., Tribouilloy C., Haggendorff A., Monin J.L., Badano L., Zamorano J.L., Sicari R., Vahanian A., Roelandt J.R.T.C. 2010. European association of echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). *European Heart Journal Cardiovascular Imaging*; 11:307-332.
- Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. 2006. Recommendations for chamber quantification. *Eur J Echocardiography*; 7, 79-108.
- Li H., Tago K., Io K., Kuroiwa, K., Arai T., Iwahana H., Tominaga S., Yanagisawa K. 2000. The Cloning and Nucleotide Sequence of Human ST2L cDNA. *Genomics*. 67:284-290.

- Lilly L. S. 2011. Pathophysiology of Heart Disease - A Collaborative Project of Medical Students and Faculty 5th. Philadelphia: Lippincott, Williams and Wilkins. Jung JW. 2007. Pulmonary arterial hypertension of congenital heart disease: from reversible pulmonary hypertension to eisenmenger syndrome. *Korean Circulation*; 37:287-297.
- Lin Y.H., Zhang R.C., Hou L.B., Wang K.J., Ye Z.N., Huang T., Zhang J., Chen X., Kang J.S. 2016. Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. *Diabetes Res Clin Pract.* 118:140-5.
- Lindsay J., Hillis L. 2007. Clinical update: atrial septal defect in adults. *Lancet*; 369:1244-1246.
- Lourenco A.P., Fontoura D., Henriques-Coelho T., Leite-Moreira A.F. 2012. Current pathophysiological concepts and management of pulmonary hypertension. *Int J Cardiol*; 155:350-361.
- Luk K.S., Ip C., Gong M.Q., Wong S.H., Wu W.K., Dong M., Li G.P., Chan K.P., Du Y.M., Liu T., Wong M.C., Tse G. 2017. *J Geriatr Cardiol.* 14: 766-771.
- Martin M.U. 2013. Seminars in Immunology Special aspects of interleukin-33 and the IL-33 receptor complex. *Seminars in Immunology.* 25(6):449-457.
- Martin S.S., Shapiro E.P., Mukherjee M. 2014. Atrial Septal Defects – Clinical Manifestations, Echo Assessment, and Intervention. *Clin Med Insights Cardiol.* 8(Suppl 1): 93-98.
- Mancia G., Fagard R., Narkiewicz K., Redón J., Zanchetti A., Böhm M., *et al.* 2013. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens.* 2013 Jul;31(7):1281-357.
- Mueller T., Dieplinger B. 2013. The Presage® ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. *Expert. Rev Mol Diagn*; 13: 13-30.
- Pascual-Figal, D. A. dan Januzzi, J. L. 2015. The Biology of ST2: The International ST2 Consensus Panel. *The American Journal of Cardiology.* 115(7 Suppl):3B-7B.
- Post M. C. 2013. Association between pulmonary hypertension and an atrial septal defect. *Neth Heart J.* 21:331-332
- Rahayuningsih S.E.. 2009. Hubungan antar hipertensi pulmonal pada defek septum atrium sekundum dan mutasi gen. *Sari Pediatri*; 11:113-117.
- Richards, A. M., Di Somma, S., Mueller, T. 2015. ST2 in stable and unstable ischemic heart diseases. *The American journal of cardiology.* 115(7 Suppl):48B-58B. Sanada S., Hakuno D., Higgins L.J. 2007. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. *J Clin Investig.*; 117:1538-1549.
- Rojas C.A., El-Sherief A., Medina H.M., Chung J.H., Choy G., Ghoshhajra B.B., Abbara S. 2010. Embryology and Developmental Defects of the Interatrial Septum. *American Journal of Roentgenology.* 195:5, 1100-1104.
- Rudski L.G., Lai W.W., Afilalo J., Hua L., Handschumacher M.D., Chandrasekaran K., Solomon S.D., Louie E.K., Schiller N.B. 2000. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the american society of echocardiography. *J Am Soc Echocardiogr*; 23:685-713.
- Sanada S., Hakuno D., Higgins L. J., Schreiter E. R., Mckenzie A. N. J., Lee R.T. 2007. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. *J Clin Invest.* 117(6):1538-1549. Sommer RJ, Hijazi ZM, Rhodes JF. 2008. Pathophysiology of congenital heart disease in adult. *Circulation*; 117:1090-1099.

- Schmitz J., Owyang, A., Oldham, E., Song Y., Murphy E., Mcclanahan T. K., Zurawski G., Moshrefi M., Qin J., Li X., Gorman D. M., Bazan J. F., Kastelein R. A. 2005. IL-33 , an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. *Immunity*. 23:479–490.
- Shao D., Perros F., Caramori G., Meng C., Dormuller P., Chou P.C., *et al.* 2014. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. *Biochem Biophys Res Commun*. 451(1):8-14.
- Shimpo, M., Morrow, D.A., Weinberg, E.O., *et al.* 2004. Serum levels of the interleukin-1 receptor family member ST2 predicts mortality and clinical outcome in acute myocardial infarction. *Circulation*, 109(18), 2186–2190
- Sommer R.J., Hijazi Z.M., Rhodes J.F. 2008. Pathophysiology of Congenital Heart Disease Villacorta H., Maisel A.S. 2016. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. *Arq Bras Cardiol*. 106(2):145-152
- Warnes C.A., Williams R.G., Bashore T.M., Child J.S., Connolly H.M., Dearani J.A., Nido P., Fasules J.W., *et al.* 2008. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary. *Circulation*. 118:2395-2451
- Willems S., Sels J.W., Flier S., Versteeg D., Buhre W.F., de Kleijn D.P., Hoefler I.E, Pasterkamp G. 2013. Temporal changes of soluble ST2 after cardiovascular interventions. *Eur J Clin Invest*. 43: 113–120.
- Zheng Y.G, Yang T., He J.G., Chen G., Liu Z.H., Xiong C.M., *et al.* 2014. Plasma Soluble ST2 Levels Correlate With Disease Severity and Predict Clinical Worsening in Patients With Pulmonary Arterial Hypertension. *Clin. Cardiol*. 37, 6, 365–370.